000			01788nam a2200421 i 4500
999			_c283201 _d283201
001			on1106013346
003			OCoLC
005			20190730190528.0
006			m o d f
007			cr bn|||||||||
008			190628s2019 dcu o f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1016-C (online)
086	0		_aY 4.OV 2:116-01
088			_aSerial no. 116-01 (United States. Congress. House. Committee on Oversight and Reform)
099			_aY 4.OV 2:116-01
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Oversight and Reform,
245	1	0	_aExamining the actions of drug companies in raising prescription drug prices : _bhearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, January 29, 2019.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2019.
300			_a1 online resource (iii, 57 pages)
336			_btxt
337			_2rdamedia _bn
338			_2rdacarrier _bnc
500			_a"Serial no. 116-01."
500			_aCRDP Program record.
588			_aDescription based on online resource; title from PDF title page (govinfo, viewed June 28, 2019).
856	4	0	_3PDF version _uhttps://purl.fdlp.gov/GPO/gpo122460
856	4	0	_3Text version _uhttps://purl.fdlp.gov/GPO/gpo122497
050		4	_aKF27 _b.O96 2019a
650		0	_aPrescription pricing _xGovernment policy _zUnited States.
650		0	_aPharmaceutical industry _xGovernment policy _zUnited States.
650		0	_aDrugs _zUnited States _xCost control.
650		0	_aDrugs _xPrices _xHealth aspects _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8